ME01546B - Liksisenatid kao dodatna terapija insulin glarginu i metforminu za liječenje dijabetesa tipa 2 - Google Patents
Liksisenatid kao dodatna terapija insulin glarginu i metforminu za liječenje dijabetesa tipa 2Info
- Publication number
- ME01546B ME01546B MEP-2012-147A MEP14712A ME01546B ME 01546 B ME01546 B ME 01546B ME P14712 A MEP14712 A ME P14712A ME 01546 B ME01546 B ME 01546B
- Authority
- ME
- Montenegro
- Prior art keywords
- pharmaceutically acceptable
- combination
- metformin
- acceptable salt
- use according
- Prior art date
Links
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 title claims 8
- 229960003105 metformin Drugs 0.000 title claims 8
- 108010057186 Insulin Glargine Proteins 0.000 title claims 6
- COCFEDIXXNGUNL-RFKWWTKHSA-N Insulin glargine Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(=O)NCC(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 COCFEDIXXNGUNL-RFKWWTKHSA-N 0.000 title claims 6
- 229960002869 insulin glargine Drugs 0.000 title claims 6
- 208000001072 type 2 diabetes mellitus Diseases 0.000 title claims 6
- XVVOERDUTLJJHN-UHFFFAOYSA-N Lixisenatide Chemical compound C=1NC2=CC=CC=C2C=1CC(C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(CC(N)=O)C(=O)NCC(=O)NCC(=O)N1C(CCC1)C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N1C(CCC1)C(=O)N1C(CCC1)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)CC)NC(=O)C(NC(=O)C(CC(C)C)NC(=O)C(CCCNC(N)=N)NC(=O)C(NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(CCC(O)=O)NC(=O)C(CCC(O)=O)NC(=O)C(CCSC)NC(=O)C(CCC(N)=O)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(CC(O)=O)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC=1C=CC=CC=1)NC(=O)C(NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)CNC(=O)C(N)CC=1NC=NC=1)C(C)O)C(C)O)C(C)C)CC1=CC=CC=C1 XVVOERDUTLJJHN-UHFFFAOYSA-N 0.000 title 1
- 229960001093 lixisenatide Drugs 0.000 title 1
- 108010004367 lixisenatide Proteins 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 150000003839 salts Chemical class 0.000 claims 11
- XVVOERDUTLJJHN-IAEQDCLQSA-N lixisenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 XVVOERDUTLJJHN-IAEQDCLQSA-N 0.000 claims 5
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 2
- 108090001061 Insulin Proteins 0.000 claims 2
- 102000004877 Insulin Human genes 0.000 claims 2
- 239000008103 glucose Substances 0.000 claims 2
- 229940125396 insulin Drugs 0.000 claims 2
- 102000017011 Glycated Hemoglobin A Human genes 0.000 claims 1
- 108010014663 Glycated Hemoglobin A Proteins 0.000 claims 1
- 238000011374 additional therapy Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000000291 postprandial effect Effects 0.000 claims 1
- -1 salts salt Chemical class 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Diabetes (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (12)
1. Kombinacija za upotrebu u lečenju dijabetes melitusa tipa 2, naznačena time, što sadrži (a) desPro36Eksendin-4(1-39)-Lys6-NH2 i/ili a njegovu farmaceutski prihvatljivu so, (b) insulin glargine i/ili njegovu farmaceutski prihvatljivu so, i (c) metformin i/ili njegovu farmaceutski prihvatljivu so.
2. Kombinacija za upotrebu prema zahtevu 1, naznačena time, što desPro36Eksendin-4(1-39)-Lys6-NH2 i/ili njegova farmaceutski prihvatljiva so je subkutano administriran .
3. Kombinacija za upotrebu prema prema zahtevu 1 ili 2, naznačena time, što je insulin glargin i/ili njegova farmaceutski prihvatljiva so subkutano administriran.
4. Kombinacija za upotrebu prema jednom od zahteva 1 do 3, naznačena time, što je metformin oralno administriran.
5. Kombinacija za upotrebu prema jedno od prethodnih zahteva, naznačena time, što je desPro36Eksendin-4(1-39)-Lys6-NH2 i/ili njegova farmaceutski prihvatljiva so administriran kao dodatna terapija admisnitraciji metformina i insulin glargina.
6. Kombinacija za upotrebu prema jednom od prethodnih zahteva, naznačena time, što je subjekt koji se tretira, odraslo lice.
7. Kombinacija za upotrebu prema jednom od prethodnih zahteva, naznačena time, što dijabetes melitus tipa 2 nije adekvatno kontrolisan samo metforminom i insulinom.
8. Kombinacija za upotrebu prema 7, naznačena time, što tretman samo dozom od najmanje 1.5 g/dan metformina i najmanje 10 jedinica /dan insulina tokom tri meseca adekvatno ne kontroliše dijabetes melitus tipa 2.
9. Kombinacija za upotrebu prema jednom od prethodnih zahteva, naznačena time, što subjekat koji se tretira ima vrednosti za HbA1 c u opsegu od 7% do 10% i/ili koncetraciju glukoze u plazmi, natašte od najmanje 7 mmol/L i/ili 2 h postprandialnu glukozu u plazmi od najmanje 11.1 mmol/L.
10. Farmaceutska kombinaciaj koja sadrži (a) desPro36Eksendin-4(1-39)-Lys6-NH2 i/ili njegovu farmaceutski prihvatljivu so, (b) insulin glargina i/ili njegovu farmaceutski prihvatljivu so, i (c) metformin i/ili njegovu farmaceutski prihvatljivu so.
11. Kombinacija prema zahtevu 10, naznačena time, što je za uptorebu u lečenju dijabetes melitusa tipa 2.
12. Upotreba kombinacije (a) desPro36Eksendin-4(1-39)-Lys6-NH2 i/ili njegove farmaceutski prihvatljive soli, (b) insulin glargina i/ili njegove farmaceutski prihvatljive soli i (c) metformin i/ili njegove farmaceutski prihvatljive soli, za proizvodnju farmaceutske kompozicije za lečenje dijabetes melitusa tipa 2.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09175877.1A EP2329848B2 (en) | 2009-11-13 | 2009-11-13 | Lixisenatide as add-on therapy to insulin glargine and metformin for treating type 2 diabetes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME01546B true ME01546B (me) | 2014-04-20 |
Family
ID=41800749
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2012-147A ME01546B (me) | 2009-11-13 | 2009-11-13 | Liksisenatid kao dodatna terapija insulin glarginu i metforminu za liječenje dijabetesa tipa 2 |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP2329848B2 (me) |
| CY (1) | CY1113755T1 (me) |
| DK (1) | DK2329848T4 (me) |
| ES (1) | ES2398012T5 (me) |
| HR (1) | HRP20121029T4 (me) |
| ME (1) | ME01546B (me) |
| PL (1) | PL2329848T5 (me) |
| PT (1) | PT2329848E (me) |
| RS (1) | RS52629B2 (me) |
| SI (1) | SI2329848T2 (me) |
| SM (1) | SMT201300013B (me) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3228320T (pt) | 2008-10-17 | 2020-03-26 | Sanofi Aventis Deutschland | Combinação de uma insulina e de um agonista do glp-1 |
| KR101853606B1 (ko) | 2009-07-06 | 2018-05-03 | 사노피-아벤티스 도이칠란트 게엠베하 | 메티오닌을 함유하는 수성 인슐린 제제 |
| KR101337322B1 (ko) | 2009-11-13 | 2013-12-06 | 사노피-아벤티스 도이칠란트 게엠베하 | Ｇｌｐ-1 효능제 및 메티오닌을 포함하는 약제학적 조성물 |
| DK2498802T3 (en) | 2009-11-13 | 2015-04-13 | Sanofi Aventis Deutschland | Pharmaceutical composition comprising a GLP-1 agonist, insulin and a methionine |
| AU2011202239C1 (en) | 2010-05-19 | 2017-03-16 | Sanofi | Long-acting formulations of insulins |
| ES2606554T3 (es) | 2010-08-30 | 2017-03-24 | Sanofi-Aventis Deutschland Gmbh | Uso de AVE0010 para la fabricación de un medicamento para el tratamiento de la diabetes mellitus de tipo 2 |
| RU2572703C2 (ru) * | 2011-02-02 | 2016-01-20 | Санофи-Авентис Дойчланд Гмбх | Предотвращение гипогликемии у пациентов с сахарным диабетом 2 типа |
| US9821032B2 (en) * | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
| PL2750699T3 (pl) | 2011-08-29 | 2015-12-31 | Sanofi Aventis Deutschland | Kombinacja farmaceutyczna do stosowania w kontroli glikemii u pacjentów z cukrzycą typu 2 |
| AR087744A1 (es) | 2011-09-01 | 2014-04-16 | Sanofi Aventis Deutschland | Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa |
| MY170713A (en) * | 2011-10-28 | 2019-08-27 | Sanofi Aventis Deutschland | Treatment protocol of diabetes type 2 |
| MX369511B (es) | 2013-04-03 | 2019-11-11 | Sanofi Sa | Tratamiento de la diabetes mellitus mediante formulaciones de insulinas de acción prolongada. |
| SG10201710347PA (en) * | 2013-06-17 | 2018-01-30 | Sanofi Aventis Deutschland | Insulin glargine/lixisenatide fixed ratio formulation |
| AU2015359376B2 (en) | 2014-12-12 | 2021-09-09 | Sanofi-Aventis Deutschland Gmbh | Insulin glargine/lixisenatide fixed ratio formulation |
| TWI748945B (zh) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患治療 |
| TW201705975A (zh) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患之治療 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1076066A1 (en) | 1999-07-12 | 2001-02-14 | Zealand Pharmaceuticals A/S | Peptides for lowering blood glucose levels |
-
2009
- 2009-11-13 ME MEP-2012-147A patent/ME01546B/me unknown
- 2009-11-13 SI SI200930473T patent/SI2329848T2/sl unknown
- 2009-11-13 PT PT91758771T patent/PT2329848E/pt unknown
- 2009-11-13 DK DK09175877.1T patent/DK2329848T4/da active
- 2009-11-13 RS RS20120571 patent/RS52629B2/sr unknown
- 2009-11-13 PL PL09175877T patent/PL2329848T5/pl unknown
- 2009-11-13 ES ES09175877T patent/ES2398012T5/es active Active
- 2009-11-13 EP EP09175877.1A patent/EP2329848B2/en active Active
-
2012
- 2012-12-13 HR HRP20121029TT patent/HRP20121029T4/hr unknown
-
2013
- 2013-01-09 CY CY20131100022T patent/CY1113755T1/el unknown
- 2013-01-30 SM SM201300013T patent/SMT201300013B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HRP20121029T4 (hr) | 2019-10-18 |
| PT2329848E (pt) | 2013-01-23 |
| ES2398012T5 (es) | 2020-02-26 |
| SI2329848T1 (sl) | 2013-02-28 |
| PL2329848T5 (pl) | 2019-12-31 |
| RS52629B2 (sr) | 2019-11-29 |
| DK2329848T3 (da) | 2013-02-04 |
| SMT201300013B (it) | 2013-03-08 |
| EP2329848B2 (en) | 2019-06-19 |
| PL2329848T3 (pl) | 2013-05-31 |
| HRP20121029T1 (hr) | 2013-01-31 |
| RS52629B (sr) | 2013-06-28 |
| DK2329848T4 (da) | 2019-09-09 |
| ES2398012T3 (es) | 2013-03-13 |
| CY1113755T1 (el) | 2016-07-27 |
| EP2329848A1 (en) | 2011-06-08 |
| SI2329848T2 (sl) | 2019-10-30 |
| EP2329848B1 (en) | 2012-10-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20121029T4 (hr) | Liksisenatid kao pomoćna terapija uz inzulin glargin i metformin kod liječenja dijabetesa tip 2 | |
| HRP20151230T1 (hr) | Liksisenatid kao dodatak metforminu kod lijeäśenja dijabetesa tipa 2 | |
| AR081254A1 (es) | Composicion farmaceutica que comprende ave0010 e insulina glargina | |
| JP2017538705A5 (me) | ||
| RU2012123739A (ru) | Фармацевтическая композиция, содержащая агонист гпп-1 и метионин | |
| HRP20161620T1 (hr) | Uporaba ave0010 za proizvodnju lijeka za liječenje dijabetes melitusa tip 2 | |
| JP2011241213A5 (me) | ||
| HRP20150353T1 (hr) | Farmaceutski pripravak koji sadrži glp-1 agonist, inzulin i metionin | |
| FI3229828T3 (fi) | Glargiini-insuliinin/liksisenatidin vakiosuhteinen formulaatio | |
| HRP20141080T1 (hr) | Farmaceutski pripravci s (1s) -1,5-anhidro-1 [5-(4-etoksibenzil)-2-metoksi-4-metilfenil]-1-tio-d-glucitolom i sekretagogom inzulina | |
| RU2018120182A (ru) | Плазминоген-заместительная терапия при дефиците плазминогена | |
| RU2015132860A (ru) | Композиции инсулинов длительного действия | |
| NZ608829A (en) | Pharmaceutical composition comprising an sglt2-inhibitor, methods for treating and uses thereof | |
| MX2012006744A (es) | Tiazolidinadionas reguladores de receptores activados por proliferador de peroxisoma (ppar) y combinaciones para el tratamiento de diabetes mellitus y otras enfermedades metabolicas. | |
| HRP20151369T1 (hr) | Liksisenatid i metformin za lijeäśenje dijabetesa tipa 2 | |
| JP2018533589A5 (me) | ||
| BR112013019744A2 (pt) | prevenção de hipoglicemia em pacientes com diabetes mellitus tipo 2 | |
| ME02277B (me) | Postupak za prečišćavanje rekombinantnog fsh | |
| WO2016060517A3 (ko) | 신규한 3-(4- (벤질옥시)페닐)핵스- 4-이노익 산 유도체 및 다른 유효 성분을 포함하는 대사성 질환의 예방 또는 치료용 복합제제 | |
| SI2576524T1 (en) | USE OF METFORMIN IN COMBINATION WITH GLUCOIN-ACTIVE ACTIVATORS, ALSO THE COMPOSITION, COMPARING METFORMIN AND GLUCOIN-ACTIVE ACTUATOR | |
| JP2017502074A5 (me) | ||
| RU2016114098A (ru) | Новое производное аналога инсулина | |
| MX2014013091A (es) | Composicion farmaceutica. | |
| JP2018509419A5 (me) | ||
| WO2018005794A3 (en) | Novel non-systemic tgr5 agonists |